Despite the headwinds facing the industry, a growing number of leading pharmaceutical companies feature on Thomson Reuters’ annual Top 100 Global Innovators list, as Bob Stembridge reports.
Life sciences companies do not do research and development (R&D) like everyone else. With longer innovation cycles, several well-defined layers of regulatory approval and various global hurdles to overcome, patent volumes in the pharmaceutical industry are often dwarfed by those of fast-moving industries such as semiconductors and consumer electronics, which tend to steal the spotlight when it comes to showcasing innovation.
Does that make pharma companies any less innovative? No. In fact, despite the obvious headwinds facing the industry, a growing number of leading pharmaceutical companies have been showing up on Thomson Reuters’ annual Top 100 Global Innovators list.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Thomson Reuters’ annual Top 100 Global Innovators list; patents; innovation; pharmaceutical